The National Company Law Tribunal (NCLT) approves the merger of **Piramal Enterprises** into **Piramal Finance**. **Anand Piramal** assumes the role of chairman, while **Jairam Sridharan** is appointed as managing director and CEO of the combined entity. The restructuring consolidates operations under a unified leadership structure.
Piramal Enterprises completes its merger with Piramal Finance by September. The consolidation follows strategic restructuring to streamline operations under the Piramal Group. The move aims to integrate financial services with core business divisions, though specific terms or impacts remain undisclosed.
Piramal Pharma Limited (PPL) debuts on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The company’s listing ceremony features key executives, including Chairman Ajay Piramal, PPL Chairperson Nandini Piramal, and CEO Peter DeYoung. PPL operates under the Piramal Group, specializing in pharmaceuticals.
Piramal Enterprises plans to split its financial services and pharmaceutical operations into two distinct listed companies. The pharma business will transfer to **Piramal Pharma**, while **PHL Fininvest** will merge with Piramal Enterprises to form a new non-banking financial company (NBFC). The restructuring aims to streamline operations and enhance shareholder value by separating core business verticals.